Steatohepatitis, nonalcoholic

Metabolic liver disease Hemochromatosis Wilson s disease < 1-Antitrypsin deficiency Nonalcoholic steatohepatitis ("fatty liver")... [Pg.253]

Caballero, F., Fernandez, A., Matias, N., Martinez, L., Fucho, R., Elena, M., Caballeria, J., Morales, A., Fernandez-Checa, J. C., and Garcia-Ruiz, C. (2010). Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis Impact on mitochondrial s-adenosyl-l-methionine and GSH. /. Biol. Chem. doi 10.1074/jbc.M109.099333. [Pg.240]

Working at 3.0T with proton decoupling, Sevastianova et al. partially resolved the resonance of nicotinamide adenine dinucleotide phosphate (NADPH) from that of a-NTP. ° NADPH was higher in subjects with nonalcoholic steatohepatitis and cirrhosis than in healthy controls and correlated with disease severity. Solga et al. investigated the reliability of both and P MRS at 1.5 T in cohorts of obese diabetic subjects and healthy con-trols. ° Whereas hepatic fat could be reliably measured with relative ease, hepatic ATP proved difficult with obese subjects due to reduced P SNR. [Pg.143]

Dolzhenko M, Shipulin V, Sokolova L (2005) Role of enterosorption in hypolipidemic therapy of patients with nonalcoholic steatohepatitis with concominant IHD and diabetes meUitus type 11. Mystetstvo likuvannya 9 65-66 (In Russian)... [Pg.219]

Nonalcoholic steatohepatitis (accumulation of triacylglycerol in the liver) or NASH is beginning to be identified more often in overweight individuals. This condition may progress to cirrhosis (fibrosis and loss of normal lobular structure) of the liver. In the case of T.F., measurement of serum levels of AST, ALT. and GGT were used to rule out abnormal liver function. [Pg.248]

Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004 24 3-20. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 917-923. Wanless IR, Lentz JS. Eatty liver hepatitis (steatohepatitis) and obesity an autopsy study with analysis of risk factors. Hepatology 1990 12 1106-1110. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals in the liver, 2nd edn. Philadelphia Lippincott Williams Wilkins, 1999. Mason P. Cystic fibrosis - the disease. Hosptal Pharmacist 2005 12 201-207. Tolman KG, Eonseca V, Tan MH, et al. Narrative review hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004 141 946-956. [Pg.72]

Kiyici M, Gulten M, Gurel S, et al. (2003) Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol... [Pg.254]

Metabolic Ih/er disease Hemochromatosis Wilson s disease a titiypsin deficiency Nonalcoholic steatohepatitis (l atty liveO Cholestatic Ih/er diseases Primary biliary cirrhosis... [Pg.240]

Chemicals that damage mitochondrial structure, enzymes, or DNA synthesis can disrupt beta oxidation of hpids and oxidative energy production within hepatocytes. Prolonged interruption of beta oxidation leads to micro-vesicular steatosis which can progress to macrovesicular steatosis. This sequence of events has been noted with alcoholic and nonalcoholic steatohepatitis. The role of mitochondria has been extensively studied with nonalcoholic fatty hver disease, a major issue in human medicine. Alcoholic steatosis and other forms of hepatic steatosis have been linked to impairment of ATP homeostasis and mitochondrial abnormalities have been reported in a growing body of hterature. [Pg.556]

Development of fatty liver hepatitis progressing to fatty fibrosis (50%) or cirrhosis (15%) (e.g. via nonalcoholic steatohepatitis)... [Pg.586]

Denk, H., Stumptner, C., Fuchsbichler, A., Zatloukal, K. Alcoholic and nonalcoholic steatohepatitis. Histopathologic and pathogenetic... [Pg.628]

Eriksson, S., Eriksson, K.-F., Bondesson, L. Nonalcoholic steatohepatitis in obesity a reversible condition. Acta Med. Scand. 1986 220 ... [Pg.628]

Harrison, S.A., Torgerson, S., Hayashi, R, Ward, J., Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Amer. J. Gastroenterol. 2003 98 2485-2490... [Pg.628]

Koruk, M., Savas, C., Yilmaz, O., Taysi, S., Karokok, M., Gundogdu, C., Yilmaz, A. Serum lipids, lipoproteins and apolipoprotein levels in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2003 37 177-182... [Pg.628]

Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J. Nonalcoholic steatohepatitis Majo Clinic experiences with a hitherto unnamed disease. Majo Clin. Proc. 1980 55 434-438... [Pg.628]

Neuschwander-Tetri, B.A., Brunt, EJM., Wehmeier, K.R., Oliver, D., Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma Hgand rosiglitazone. Hepatology 2003 38 1008-1017... [Pg.628]

Shimada, M., Hashimoto, E., Kaneda, H., Noguchi, S., Hayashi, N. Nonalcoholic steatohepatitis risk factors for Hver fibrosis. Hepatol. Res. 2002 24 429 -438... [Pg.628]

Tajlrl, K., Takenawa, H., Yamaoka, K., Yamane, M., Marumo, R, Sato, C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J. Clin. Gastroenterol. 1997 25 538-540... [Pg.628]

Zamin, L, Alves-de-Mattos, A., Zettler, C.G. Nonalcoholic steatohepatitis in nondiabetic obese patients. Can. J. Gastroenterol. 2002 16 303-307... [Pg.628]

Molloy, R.M., Komorowski, R., Varma, R.R. Recurrent nonalcoholic steatohepatitis and cirrhosis after hver transplantation. Liver Transplant. Surg. 1997 3 177-178... [Pg.890]

Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troghtazone in a patient with nonalcoholic steatohepatitis and diabetes melhtus. Am J Gastroenterol 2001 96 1631-4. [Pg.579]

Nonalcoholic steatohepatitis is the most common cause of aminotransferase increases other than viral and alcoholic hepatitis. Increased transaminase concentrations have been observed in extrahepatic cholestasis, with activities tending to be higher the more chronic the obstruction. The aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper reference limit to four to five times higher, with an AST/ ALT ratio greater than 1. The ratio s elevation can reflect the grade of fibrosis in these patients. This appears to be attributable to a reduction of ALT production in a damaged liver. Twofold to fivefold elevations of both enzymes occur... [Pg.605]

Tilg H, Dielhl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. New Engl J Med 2000 343 1467-76. [Pg.741]

Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis... [Pg.1811]

Ludwig J, Viggiano T, McGill D, Oh B. Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980 55 434-8. [Pg.1837]

Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis Summary of an AASLD single topic conference. Hepatology 2003 37 1202-19. [Pg.1839]

Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis a multicenter validation study. Hepatology 50(4) 1072-1078. doi 10.1002/hep.23050... [Pg.475]

Other Nonalcoholic steatohepatitis, sarcoidosis, gastric bypass... [Pg.694]

Obesity has been recognized as a poor prognostic variable for outcomes associated with therapy for chronic HCV. Patients with a body mass index of >30 kg/m had a 77% lower chance of response to therapy compared to overweight and normal-weight patients. The exact mechanism of this interaction between weight and effect is not known. However, the natural progression of disease may be faster in obese patients and may be related to nonalcoholic steatohepatitis. ... [Pg.754]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...